Mirum Pharmaceuticals, Inc. promoted Peter Radovich, previously the Company?s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company?s President and Chief Executive Officer, continuing to serve as the Company?s Chief Executive Officer, each effective as of January 16, 2024. Peter Radovich, 45, has served as the Company?s Chief Operating Officer since April 2020. Previously, Mr. Radovich worked in various positions at Global Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice president, operations and executive vice president, operations.

During his tenure at Global Blood Therapeutics, Mr. Radovich was responsible for the company?s technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From 2013 to 2014, Mr. Radovich served as Vice President, Global Product Leader ? Kyprolis at Onyx Pharmaceuticals, Inc., which was acquired by Amgen, Inc., where he led the company?s global, cross-functional product team responsible for the development and commercialization of Kyprolis®.

Between 2006 and 2013, he held a variety of roles of increasing responsibility in Onyx?s commercial organization supporting Kyprolis and Nexavar® and was a key member of the deal team for Onyx?s acquisition of Proteolix. From 2004 to 2006, Mr. Radovich was at Chiron Corporation (acquired by Novartis AG) in product marketing supporting Proleukin® (interleukin-2) in multiple oncology indications. Mr. Radovich received a B.A. in biology and chemistry from Texas Christian University and an MBA from Washington University in St.

Louis.